Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study

Archives of Internal Medicine

Volumn 158, Issue 14, 1998, Pages 1513-1521

  Gulløv, Annette Lemche ^a,e   Koefoed, Birgitte Gade ^a   Petersen, Palle ^b   Pedersen, Trine Sander ^a   Andersen, Ellen Damgaard ^a   Godtfredsen, John ^c   Boysen, Gudrun ^d  

^a Copenhagen Gen Practitioners Lab ^*  (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; DENMARK; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; WARFARIN;

EID: 0031852543     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.14.1513     Document Type: Article

References (23)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
3. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;28:175-179.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
5. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
6. Connolly SJ, Laupacis A, Gent M, et al, for the CAFA Study Coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991; 18:349-355.
7. Ezekowitz MD, Bridgers SL, James KE, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-1412.
8. EAFT (European Atrial Fibrillation) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
9. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
10. Prystowsky EN, Benson W, Fuster V. Management of patients with atrial fibrillation. Circulation. 1996;93:1262-1277.
11. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950-1953.
12. Lip GYH, Tean KN, Dunn F. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994;71:92-95.
13. McCrory DC, Matchar DB, Samsa G, Sanders LL, Prichett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
14. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med. 1997;157:441-445.
15. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
16. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during anti-thrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156: 409-416.
17. Koefoed BG, Gulløv AL, Petersen P. The second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulant Therapy Study (AFASAK 2): methods and design. J Thromb Thrombolysis. 1995;2:125-130.
18. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
19. Hylek EM, Skatts SJ, Sheehan MA, Singer D. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
20. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent ischemia. N Engl J Med. 1995;333:5-10.
21. Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke. 1997;28:1015-1021.
22. Kaplan EL, Meter P. Nonparametric estimation from incomplete estimations. J Am Stat Assoc. 1958;53:457-481.
23. Cox D. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.